Innovative Strategy for Resistant Depression and Suicidal Ideation: HEOR Analysis From the Perspective of BRAZIL / LATAM / LMIC .
Moderator
ELIO TANAKA, MD, TNK MEDICAL AUDIT INSTITUTION, CURITIBA, Brazil
Speakers
ELAINE BREGOLA; Helena Maria Romcy, MSc, MD; Goldete Priszkulnik, MSc, MD; JOSE MARIO ALVES JUNIOR, PhD, UNIMED CAMPINAS, BARUERI, Brazil
OBJECTIVES: We study the chance of a possible decrease in suicide ideation rates, based on scientific data and informations from a promising innovation strategy based on clinical end point.
METHODS: From database of the Notifiable Diseases Information System (SINAN) & Suicide data from the Mortality Information System (SIM) of the year 2022. A total of 496,583 cases of suicide from 2019 to 2022 in Brazilian scenario and a suicide attempt due to exogenous intoxication a subtotal of 4,259 cases, in one specific State (Brazil ). Data from international literature showing a strategy using esketamine intranasal and antidepressant treatment decreased: the risk of relapse by 51% (Hazard Ratio [HR], 0.49; 95% ci, 0.29-0.84) among patients who achieved stable remission, and 70% (HR, 0.30; 95% ci, 0.16-0.55) among those who achieved stable response compared to treatment with antidepressants and placebo.
RESULTS: We speculate that 51% (Hazard Ratio [HR] of 496,583 CASES, means that esketamine and antidepressant treatment decreased the risk of relapse to avoidance risk of suicidal ideation in 253.257 cases. The 2,172 / 4,259 cases of attempted suicide reported in exogenous intoxication data, could contemplate the chances of rescue from “de novo" treatments and better clinical outcomes.
CONCLUSIONS: For patients who have experienced remission or response after treatment with esketamine, there is a chance to resume a new treatment protocol in order to avoid loss of life or loss of productivity in cases of sequelae/suicide attempt. However, lengthy follow-up is needed in order to answer to this, with regard to economic impact and other outcomes.
METHODS: From database of the Notifiable Diseases Information System (SINAN) & Suicide data from the Mortality Information System (SIM) of the year 2022. A total of 496,583 cases of suicide from 2019 to 2022 in Brazilian scenario and a suicide attempt due to exogenous intoxication a subtotal of 4,259 cases, in one specific State (Brazil ). Data from international literature showing a strategy using esketamine intranasal and antidepressant treatment decreased: the risk of relapse by 51% (Hazard Ratio [HR], 0.49; 95% ci, 0.29-0.84) among patients who achieved stable remission, and 70% (HR, 0.30; 95% ci, 0.16-0.55) among those who achieved stable response compared to treatment with antidepressants and placebo.
RESULTS: We speculate that 51% (Hazard Ratio [HR] of 496,583 CASES, means that esketamine and antidepressant treatment decreased the risk of relapse to avoidance risk of suicidal ideation in 253.257 cases. The 2,172 / 4,259 cases of attempted suicide reported in exogenous intoxication data, could contemplate the chances of rescue from “de novo" treatments and better clinical outcomes.
CONCLUSIONS: For patients who have experienced remission or response after treatment with esketamine, there is a chance to resume a new treatment protocol in order to avoid loss of life or loss of productivity in cases of sequelae/suicide attempt. However, lengthy follow-up is needed in order to answer to this, with regard to economic impact and other outcomes.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
HSD32
Topic
Health Service Delivery & Process of Care
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Mental Health (including addition), SDC: Neurological Disorders, STA: Alternative Medicine